“Continuum of care” or “end-to-end care” are the new buzzwords in healthcare, but they’re not fleeting fads. In fact, the concepts mark a significant shift in healthcare, especially in the medical devices industry, which is used to treat isolated episodes of sickness with an implant before moving on to the next sick patient.
On Thursday, Stacy Enxing Seng, president of Covidien’s Global Vascular Therapies business, talked about how her business looks at the “continuum of care” at an event organized by LifeScience Alley. I caught up with Enxing Seng after her speech to get a little more insight on the topic.
She said that in the vascular therapies business implementing the concept of “continuum of care” means “measuring productivity of our technologies not simply in the procedure, but the complete care of that patient over time and preserving treatment options for the future.”
An example would be Covidien’s TurboHawk Plaque Excision System. The device removes the plaque from the vessel, but it doesn’t leave an implant behind, Enxing Seng explained.
“And what that has the benefit of doing is ensuring that if the patient needs to be retreated, that the physician is not going through an implant, which can be very difficult to treat at that point.”
Here is the video: